shouldiuse.io

Categories

VERDICT

Should I use DFIN (Donnelley Financial Solutions)?

Financial risk, compliance and software solutions - dfinsolutions.com

Depends. Buy only if you're a public company, IPO candidate, or deal team needing SEC-grade filings, XBRL tagging, or a data room. Smaller teams will pay enterprise prices for capability they'll never use.

Confidence

Medium. Based on ~25 public sources; user-review evidence is thin (8 G2 reviews, no Gartner scores visible in snippets).

Ratings

  • Value for moneyNo public pricing evidence
  • Ease of useNo independent usability evidence
  • Feature depth
  • Support qualityOnly support portals documented, no ratings
  • Security posture

Pricing

Not disclosed

ModelNot disclosed
Monthly feesNot disclosed
HardwareNot disclosed

Best for

  • Public-company finance teams
  • IPO-track companies
  • M&A and deal teams
  • Regulatory reporting (MiFID/PRIIPs)

Not for

  • Startups not yet filing with the SEC
  • Small businesses wanting simple finance tools
  • Buyers needing transparent self-serve pricing
  • Teams wanting month-to-month, no-sales-cycle software

Gotchas - check before you buy

medium

Pricing opaque; expect negotiation — a marketplace reportedly saved 25% only after a cost review

medium

Modular products (Venue, ActiveDisclosure, Arc) can mean multiple contracts and negotiated line items

low

Support runs through portals and scheduled walkthroughs, not self-serve help

Pros and cons

Pros

  • Deep SEC/XBRL filing suite with AI-assisted tagging
  • Venue data room adds AI translation and document summaries
  • Proven at IPOs including Apnimed, PMV Pharma, MBX Biosciences
  • Named customers include Kodak and Chemours
  • Mature security program: Trust Center, SSO, published whitepapers

Cons

  • No public pricing; sales-led contact process
  • Tiny independent review base: 8 G2 reviews total
  • High costs — one customer case study touts 25% savings
  • Built for regulated filings; excessive for routine document sharing

Sources & method

Analyzed 10/05/2026 - 10 sources - No known vulnerabilities found in the sources reviewed.

official x3review x4security x2news x1

Key stats

  • Feature depth: 5/5

    Rating

  • Not disclosed

    Starting price

  • 10

    Sources

  • Analyzed

  • Value for money. No public pricing evidence
  • Ease of use. No independent usability evidence
  • Feature depth: 5/5. Full SEC, XBRL, data room, regulatory coverage
  • Support quality. Only support portals documented, no ratings
  • Security posture: 4/5. Trust Center, SSO, whitepapers; no incidents found
  • 8 G2 reviews across DFIN's product suite
  • None Public pricing quote-based enterprise sales
  • 2016 Founded spun off from R.R. Donnelley
  • NYSE: DFIN Listed publicly traded company

Pricing

Not disclosed

Security

No known vulnerabilities found in the sources reviewed.

What users say

Independent user sentiment is sparse — DFIN lists on Gartner and G2, but 8 G2 reviews appear across its products.

Companies that use it

  • Kodak
  • Chemours⁶
  • Unibail-Rodamco-Westfield
  • MBX Biosciences
  • PMV Pharma
Full analysis

Based on ~25 public sources; user-review evidence is thin (8 G2 reviews, no Gartner scores visible in snippets).

Enterprise SEC filing, XBRL and data room suite for public companies — serious overkill and opaque pricing for anyone smaller.

Methodology

Based on ~25 public sources; user-review evidence is thin (8 G2 reviews, no Gartner scores visible in snippets).

Sources

  1. official
  2. review
  3. review
  4. review
  5. review
  6. DFIN Chemours Case Studygo.dfinsolutions.com
    official
  7. security
  8. security
  9. news
  10. official

Rate this review

Anonymous. You can change your vote.

Loading votes…

Comments

One queue. No nested comments. Give a display name first. Limit: 200 words per comment and 7 comments per day. You can edit or delete yours.

Save a name to write a comment.

0 / 200 words

No comments yet.